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Highlights 
1. Vancomycin dosing in prolonged intermittent renal replacement therapy in ICU patients is 
highly challenging 
2. Assuming a MIC of 1 mg/L, vancomycin doses of 25 mg/kg/day are suggested to achieve 
efficacious, whilst minimising toxic, exposures 
3. Dosing of vancomycin during PIRRT needs to be significantly higher than what is required in 
other forms of CRRT or where there is no RRT being used 
4. The large pharmacokinetic variability of vancomycin in critically ill patients means empiric 
dosing is difficult and TDM is still required 
5. TDM is still required, perhaps more frequently as durations of PIRRT may not always be 
homogenous meaning that a static guideline approach to dosing is likely to be inadequate 
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 Abstract 
Objectives: The aim of this study was to describe the population pharmacokinetics of 
vancomycin during prolonged intermittent renal replacement therapy (PIRRT) in 
critically ill patients with acute kidney injury. 
Methods: Critically ill patients prescribed vancomycin across two sites had blood 
samples collected during 1-3 dosing intervals during which PIRRT was performed. 
Plasma samples were assayed with a validated immunoassay method. Population 
pharmacokinetic analysis and Monte Carlo simulations were performed using 
Pmetrics®. The target vancomycin exposures were an AUC0-24/MIC ratio of 400 for 
efficacy and AUC0-24 700 for toxicity. 
Results: Eleven critically ill patients (7 male) were enrolled and contributed 192 
plasma samples. The patient’s mean ± SD age, weight and BMI were 57 ± 13 years, 98 ± 
43 kg and 31 ± 9 kg/m2, respectively. A two-compartment linear model adequately 
described the data. The mean ± SD population pharmacokinetic parameter estimates 
were PIRRT clearance (CL) 3.47 ± 1.99 L/h, non-PIRRT CL 2.15 ± 2.07 L/h,  volume of 
distribution of the central compartment (Vc) 41.85 ± 24.33 L, distribution rate constant 
from central to peripheral compartment 5.97 ± 7.93 h-1 and from peripheral to central 
compartment 5.29 ± 6.65 h-1. Assuming a MIC of 1 mg/L, vancomycin doses of 25 
mg/kg/day are suggested to achieve efficacious, whilst minimising toxic, exposures. 
Conclusions: This is the first population pharmacokinetic study of vancomycin in 
patients receiving PIRRT and we observed large pharmacokinetic variability. 
Empirically, weight-based doses that are appropriate for the duration of PIRRT should 
be selected and supplemented with therapeutic drug monitoring.   
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1. Introduction 
Worldwide, approximately 2 million people die each year from acute kidney injury 
(AKI) [1]. In critically ill patients, sepsis is the most common cause [2]. Despite the 
availability of renal replacement therapy (RRT), critically ill patients with AKI still have 
mortality rates ranging from 40-60% [3] and no effective treatment currently exists to 
minimise this significant burden [1]. Approximately 5% of critically ill patients with AKI 
go on to require RRT [4, 5]. 
Prolonged intermittent renal replacement therapy (PIRRT), uses haemodiafiltration or 
dialysis for a 6- to 12- hour treatment duration depending on the needs of the patient. 
PIRRT retains the benefits of intermittent haemodialysis such as faster flow rates whilst 
still conferring the haemodynamic stability associated with continuous RRT [6]. 
Haemodiafiltration offers the highest solute flux per membrane surface area for all 
solutes, meaning that drug clearance is likely to be high with this RRT modality [7].  
Alterations in the pharmacokinetics of antibacterials can affect the likelihood of 
attaining therapeutic exposures, also described as pharmacodynamic targets. This 
appears to be particularly common in critically ill patients receiving hydrophilic 
antibiotics such as vancomycin [8]. Vancomycin pharmacokinetics appear to be 
significantly affected by forms of RRT, like PIRRT [9]. 
Vancomycin is active against Gram positive bacteria including methicillin-susceptible 
and resistant Staphylococcus aureus as well as Staphylococcus epidermidis and 
streptococci. Gram positive bacteria commonly cause sepsis [10], and as such 
vancomycin remains an important antibacterial agent in this patient population. From a 
pharmacodynamic viewpoint, vancomycin’s activity is best described using the index, 
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the area under the concentration time curve within a 24-hour period (AUC0-24) to MIC 
ratio (AUC0-24/MIC) [11]. Knowledge of the pharmacokinetics caused by PIRRT, is 
essential for understanding likely altered dosing needs that can consistently achieve 
this pharmacodynamic target. 
The aim of this study was to describe the population pharmacokinetics of vancomycin 
during PIRRT in critically ill patients with AKI and to analyse the probability of attaining 
established pharmacodynamic targets. 
2. Methods 
2.1 Setting 
This was an observational pharmacokinetic study at two intensive care units (ICU), the 
Gold Coast University Hospital, Australia and Hannover Medical School, Hannover, 
Germany. The data from Hannover Medical School had been previously published as a 
non-compartmental pharmacokinetic analysis [9]. Ethical approval was obtained from 
the local institutional Human Research Ethics Committees to conduct the study. Written 
informed consent was obtained from all participants or from their substitute decision-
makers.  
2.2 Study population  
The inclusion criteria for this study were: (i) age ≥ 18 years; (ii) admission to an 
intensive care unit; (iii) clinical indication for vancomycin; and (iv) receiving PIRRT. The 
exclusion criteria were: (i) pregnant women; (ii) patients with active bleeding; or (iii) 
patients with HIV or hepatitis. 
2.3 Study protocol 
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Vancomycin was administered at the direction of the treating physician. The timing of 
blood sampling to determine plasma vancomycin concentrations was different at the 
participating institutions.  
At Gold Coast University Hospital, blood sampling occurred via an in situ arterial 
line before the drug administration (T0) and at 15 minutes (T15), T30, T60, T120, T180, 
T300, T480 and at T600. Further arterial blood samples were collected from each 
patient to establish plasma concentrations between PIRRT sessions. Sampling occurred 
during the first dosing period and at subsequent dosing intervals where possible 
thereafter. PIRRT was commenced at the discretion of the clinician and did not 
uniformly correspond with timing of vancomycin dosing. However, actual PIRRT times 
were used in the pharmacokinetic analysis. PIRRT was performed in all patients with a 
4008S hemodialysis machine (Fresenius Medical Care, Bad Homburg, Germany) using 
Fresenius AV600S filters (surface area, 1.4 m2; Fresenius Medical Care). For each 
patient, a central vein was cannulated with a standard dialysis vascular catheter. A 
standardized prescription consisted of hemodiafiltration with a target duration of 10 h 
(with 300 ml/min of blood and dialysate flow and 50 ml/min of predilution).  
At the Medical School Hannover, vancomycin was administered 12 hours before 
PIRRT was started. On one sampling occasion, blood samples were drawn from an 
arterial line before administration of vancomycin and at 0.5, 1, 2, 4, 6, 8, and 12 hours 
after administration; before PIRRT; during PIRRT at time points 2, 4, and 6 hours; and at 
0.5, 1, 3, and 8 hours after PIRRT [9]. PIRRT was performed in all patients with a batch 
dialysis system (GENIUS, Fresenius Medical Care, Bad Homburg, Germany) with a 
polysulphone high-flux dialyzer (F60S [surface area, 1.3 m2], Fresenius Medical Care. In 
this form of PIRRT, sterile bicarbonate dialysate is filled into the 75-L tank and is 
thereafter circulated in a closed-loop circuit. During PIRRT, fresh dialysate is taken from 
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the top of the tank while the spent dialysate flows back to the bottom. The targeted 
mean blood and countercurrent dialysate flow was 160 mL/min. 
 
Other clinical and demographic data were collected on the day of plasma sampling, 
including: age, sex, total body weight (TBW), and body mass index (BMI). Serum 
albumin and creatinine concentrations (Scr) were also collected.  
2.4 Sample handling, storage and assay 
Three (3) ml blood samples were placed in an ice bath immediately and centrifuged at 
3000 rpm for 10 minutes. Plasma samples were stored at -80°C until bio-analysis. 
Vancomycin was measured in a monoclonal fluorescence polarization immunoassay 
(Abbott Laboratories, Abbott Park, IL). 
 
2.5 Population pharmacokinetic modelling 
To describe total vancomycin concentrations, one and two-compartment models were 
developed with the Nonparametric Adaptive Grid (NPAG) algorithm within the Pmetrics 
software package for R (Los Angeles, CA, version 1.5.1)[12, 13]. Elimination from the 
central compartment and intercompartmental distribution into the peripheral 
compartment (two compartment model) were modelled as first-order processes.  
 
2.5.1 Population pharmacokinetic covariate screening 
Age, gender, body weight and presence of RRT were evaluated as clinically relevant and 
physiologically plausible covariates. Covariates selection was performed using a 
stepwise linear regression from R on all covariates and Bayesian posterior parameters. 
Potential covariates were separately entered into the model and statistically tested by 
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use of the log-likelihood values. If inclusion of the covariate resulted in a statistically 
significant improvement in the log-likelihood values (p<0.05) and/or improved the 
goodness-of-fit plots, then the covariate was retained in the final model. 
 
2.5.2 Model Diagnostics 
Goodness of fit was assessed by linear regression, with an observed-predicted (both 
population- and individual-predicted concentrations) plot, coefficients of 
determination, and log-likelihood values.  Predictive performance was based on mean 
prediction error (bias) and the mean bias-adjusted squared prediction error 
(imprecision) of the population and individual prediction models. The internal validity 
of the population pharmacokinetic model was assessed by the bootstrap resampling 
method (n=1000) and normalised prediction distribution errors (NPDE) [14]. Using the 
visual predictive check (VPC) method, parameters obtained from the bootstrap method 
were plotted with the observed concentrations. NPDE plots were checked for normal 
distribution characteristics and trends in the data errors.   
 
2.5.3 Dosing simulations 
 
Monte Carlo simulations (n=1000) were employed using Pmetrics to determine the 
probability of target attainment (PTA) of achieving the predefined AUC0-24/MIC target of 
400 [15] and a target of AUC0-24>700 mg.h/L, which is the AUC breakpoint associated 
with an increased risk of nephrotoxicity [16], for varying MIC (0.5-4 mg/L) on a 
critically ill patient during the first 24 hours of treatment. A priori we considered a 
dosing regimen achieving 90% PTA to be sufficient. Where this criteria was not met, a 
balance between achieving a therapeutic and a non-toxic exposure was made to 
recommend a dose. The comparison of simulated probability of efficacy and toxicity for 
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varied doses of 10, 15, 20, 25, 30 and 35 mg/kg 12-hourly; 10, 15, 20, 25, 30 and 35 
mg/kg 24-hourly were performed for a typical 80 kg critically ill patient with AKI 
receiving PIRRT treatment (starting 6 hours after vancomycin administration) or 
receiving no PIRRT. A PIRRT duration of 12-hours was simulated to reflect a worst case 
scenario, where a high clearance of vancomycin could be expected. Doses were 
simulated for administration at a rate of 1000 mg per hour.  
 
3. Results 
3.1 Demographic and clinical data 
Eleven critically ill patients (7 male) were enrolled in the study (Hannover Medical 
School n=8; Gold Coast University Hospital n=3). In total 192 blood samples were 
collected over 1-3 sampling intervals. The demographic characteristics of the patients 
are shown in Table 1. The mean duration of PIRRT was 6 hours for the patients at the 
Gold Coast Hospital and 8 hours for the patients at the Medical School Hannover.  
3.2 Pharmacokinetic model building 
Vancomycin pharmacokinetics was best described using a two-compartment linear 
model. The goodness of fit model was improved by inclusion of parameter estimates for 
clearance in the presence of PIRRT (CLPIRRT) and the absence of PIRRT (CLnon-PIRRT). 
Addition of this covariate, but not others, resulted in a statistically significant 
improvement in the log-likelihood from the previous model (P <0.05). The addition of 
this covariate improved the agreement between the observed and population-predicted 
concentrations as well as distribution of observed data within the visual predictive 
check and so was retained in the final model.  
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The final covariate model was as follows:   
CL0=CLPIRRT*PIRRT+ CLnon-PIRRT 
 
where CL0 is the typical value of vancomycin CL, CLnon-PIRRT is the population 
parameter estimate of vancomycin CL without PIRRT; CLPIRRT is the population 
parameter estimate of vancomycin CL with PIRRT. The term PIRRT is one when PIRRT 
is on, and is zero when PIRRT is off.  
 
The mean ± SD population PK parameter estimates from the final covariate model are 
shown in Table 2. The diagnostic plots confirm the appropriateness of the final 
covariate model as shown in Figure 1.  
3.3 Dosing simulations 
Table 3 describes the probability of target attainment for efficacy (AUC0-24/MIC > 400) 
and toxicity (AUC0-24 >700 mg.h/L) for various dosing regimens for a 24-hour period 
against MIC 0.5-4 mg/L for an 80 kg critically ill patient with AKI receiving a 12-hour 
PIRRT treatment or receiving no PIRRT. Figure 2 graphically presents the probability of 
target attainment data for efficacy and toxicity for a MIC of 1 mg/L. These data show 
that increasing doses increase the likelihood of achieving the efficacy and toxicity 
targets and that depending on the scenario in terms of pathogen MIC and use of PIRRT, 
that dosing regimens can be selected based on the highest level of efficacy and lowest 
level of toxicity. No dosing regimen was able to achieve the a priori 90% PTA for efficacy 
with an acceptable risk of toxicity. Assuming an MIC of 1 mg/L and in the presence of a 
12-hour PIRRT treatment, a regimen of 25 mg/kg/day was associated with 72% 
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likelihood of an AUC0-24/MIC > 400 and a 38% likelihood of an AUC0-24 >700 mg.h/L 
which on balance was considered to be an acceptable regimen for the first 24-hours of 
treatment. 
4. Discussion  
4.1 Key findings 
This is the first population PK study of vancomycin in critically ill patients undergoing 
PIRRT. We found that vancomycin was eliminated by PIRRT with a PIRRT clearance of 
3.47 L/h, which is higher than those reported by other authors describing the PK of 
vancomycin in critically ill patients undergoing continuous renal replacement therapy 
(CRRT) 0.3 to 1.8 L/h[17, 18]. The high clearance we describe confirms the importance 
of selecting doses specific for PIRRT therapies rather than using data from continuous 
RRT therapies. We also observed high variability in pharmacokinetics (Table 2) which 
further emphasises the challenges of using a fixed dosing approach for a drug with a 
narrow therapeutic index like vancomycin and that therapeutic drug monitoring (TDM) 
will remain an important intervention to further optimise dosing of vancomycin in 
patient’s undergoing PIRRT. Our pharmacokinetic simulations suggest that vancomycin 
doses of 25 mg/kg/day should be most appropriate for patients receiving a 12-hour 
PIRRT treatment when considering achievement of therapeutic exposures and 
minimising the likelihood of toxic exposures. Indeed, we observed little difference in 
achievement of therapeutic exposures between 12- and 24-hourly administration of the 
same daily dose suggesting that frequency of vancomycin dosing does not significantly 
affect the AUC0-24/MIC. 
4.2 Relationship with previous papers 
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Despite the extensive use of vancomycin there is a dearth of information characterising 
its altered pharmacokinetics in patients receiving different forms of RRT in the ICU.  
Jamal et al performed a meta-review of the effect of various RRT settings on the 
clearance of meropenem, piperacillin and vancomycin and described the likely high 
clearances of vancomycin reported in critically ill patients undergoing hybrid RRT such 
as PIRRT [8]. The results of our study confirm these conclusions.  
The total vancomycin clearance caused by PIRRT and non-PIRRT mechanisms described 
in the present study was 5.62 L/h. This value is considerably higher than the total 
clearance values previously reported during continuous RRT [18-20]. Petejova et al 
studied vancomycin pharmacokinetics in critically ill patients undergoing high-flux 
extended daily haemodialysis (blood flow rate 200 mL/min and dialysate flow rate 500 
mL/min) and observed a total vancomycin clearance of 3.83 L/h and 4.12 L/h on days 1 
and 2 of treatment, respectively [21]. These authors described a much lower 
vancomycin clearance off RRT of 0.82 L/h and 0.50 L/h on days 1 and 2 of treatment 
respectively, than was observed in our study, mean 2.15 L/h (median 1.16 L/h). Such 
differences in the mean non-PIRRT clearance may be due to higher drug clearance in a 
small number of patients with residual renal function. Another likely contributor to the 
higher non-PIRRT clearance in our study was that there was an incomplete RRT history 
for some patients. Whilst this does not change the total clearance value observed in the 
study, it may mean the differentiation between PIRRT and non-PIRRT clearance values 
are not completely accurate.  
DelDot et al described the pharmacokinetics of vancomycin in 10 patients undergoing 
continuous veno-venous haemodiafiltration (CVVHDF) and observed a total vancomycin 
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clearance of 2.5 L/h (blood flow rate of 200 mL/min, dialysate flow rate of 1 L/h and 
predilution filtration solution flow rate of 2 L/h yielding and effluent flow of 3 L/h) [18].  
Beumier et al described vancomycin clearance in patients undergoing CRRT 
(haemodiafiltration or haemofiltration) of 2.0 L/h [22]. Patients in this study were 
administered vancomycin by continuous infusion following a loading dose 35 mg/kg.  
This study noted that the two most important covariates affecting vancomycin 
concentrations were body weight and CRRT intensity. Similarly Udy et al used 
population PK modelling to describe vancomycin pharmacokinetics in 81 critically ill 
patients undergoing CRRT (blood flow rates 100-200 mL/min and total effluent rates 
~20-40 mL/kg/h as a combination of ultrafiltration and dialysis). The authors 
described a median vancomycin clearance of 2.9 L/h [20]. 
In another vancomycin pharmacokinetics study using high-volume haemofiltration 
(HVHF; blood flow rates of 240 ± 20 mL/min and a substitution flow rate of 100 
mL/kg/h), Escobar et al described a mean vancomycin clearance of 2.7 L/h and 
concluded variable and much higher than standard vancomycin doses would be 
required to achieve therapeutic concentrations during different HVHF settings [19].  
Whilst many of the studies did not describe total vancomycin clearance (most described 
only RRT clearance), the variability in observed results and increasing clearance of 
vancomycin in patients treated with high flux RRT (3.8-4.1 L/h) and HVHF (2.7 L/h), the 
need to define vancomycin dosing in different RRT modalities needs to be studied to 
guide appropriate dosing.   
4.3 Implications of study findings 
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As previously demonstrated for gentamicin [23], dosing of vancomycin in critically ill 
patients with AKI receiving PIRRT needs to be significantly higher than what is required 
in other forms of CRRT or where there is no RRT being used. To ensure optimised 
dosing and achievement of vancomycin exposure targets associated with efficacy, and to 
avoid toxicity, loading doses of vancomycin (30 mg/kg) [24], coupled with appropriate 
maintenance doses (25-35 mg/kg 12-24-hourly depending on relative risk of efficacy 
and toxicity selected) based on the presence and duration of PIRRT should be used. The 
inherent large pharmacokinetic variability of vancomycin in critically ill patients means 
that we found that the highest likelihood for achieving AUC0-24/MIC >400 was only 72%, 
given the escalating risk of achieving a toxic exposure AUC0-24/MIC >700. Therefore, 
empiric dosing is difficult and TDM is still required, and in fact perhaps more frequently 
than in other settings because durations of PIRRT may not always be homogenous 
meaning that a static guideline approach to dosing is likely to be inadequate. Knowledge 
of the MIC of the pathogen will always be useful to help guide achievement of the PK/PD 
target, and if not known on a patient level, institutional data to support the AUC0-24/MIC 
or trough concentration target is valuable to ensure maximally effective therapy that 
has least toxicity. 
4.4 Study limitations  
Although this study is the first population PK of vancomycin in critically ill patients 
undergoing PIRRT, it has some limitations we would like to declare. Firstly, the sample 
size is relatively small and emerges from two different centres which used slightly 
different settings of PIRRT and therefore, describing all possible correlations between 
PK parameters and covariates may not have been possible due to the sample size across 
the centres, although it is hoped that the findings would be more generalisable. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Secondly, we did not measure vancomycin plasma concentrations at the site of infection 
which may provide better mechanistic data regarding the effectiveness of dosing. 
Thirdly, this study was neither designed nor powered to examine the effect of 
vancomycin exposure on patient outcome and larger studies are needed to explore this 
question further. Fourthly, we only simulated the first 24-hours of dosing and cannot 
recommend dosing thereafter, but this is typically guided by TDM rather than dosing 
algorithms. Finally, we have only simulated a limited number of clinical scenarios 
including only one PIRRT duration, PIRRT timing, as well as a small range of blood and 
dialysate flow, because we consider it too difficult to present all possible patient, 
treatment and dosing permutations. However, this paper is able to present the general 
effect of PIRRT on dosing requirements. 
 
5. Conclusion 
The results of this study suggest that empiric vancomycin doses of 25 mg/kg/day are 
required to achieve therapeutic exposures with a minimised risk of toxicity for patients 
receiving a 12-hour PIRRT treatment. TDM will continue to be an important tool for 
guiding dosing of vancomycin in critically ill patients amidst such variability in 
vancomycin pharmacokinetics in this patient population.  
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Figure 1. Diagnostic plots for the final population PK covariate model A. Population 
predicted concentrations (mg/L) versus observed concentrations (mg/L). The black 
dotted line is the line of linear regression with an R2 value of 0.599, and the black 
unbroken line is the line of x equal to y. B. Individual predicted concentrations versus 
observed concentrations. The black dotted line is the linear regression with an R2 value 
of 0.97, and the black unbroken line is the line of x equal to y; C. Visual Predictive Check 
of simulations of concentration (mg/L) versus time (h). Percentiles (with shaded 95% 
confidence intervals) are the lines shown as 95%, 75%, 50%, 25% and 5% values. 
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Figure 2. Probability of target attainment (PTA) for MIC 1 mg/L, where efficacy is 
described as AUC0-24/MIC >400 and toxicity as an AUC >700 for various doses 
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administered to an 80kg critically ill patient with AKI. Graph (A) represents a 24 hour 
dosing schedule for a patient in which a 12-hour PIRRT treatment is given; (B) PTA 
represents a 12 hour dosing schedule for a patient in which a 12-hour PIRRT treatment 
is given; (C) represents a 24 hour dosing schedule for a patient not receiving PIRRT. 
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Table 1: Demographic characteristics of included patients 
Patient Age 
(years) 
Height  
(cm) 
Sex 
(F/M) 
Weight 
(kg) 
BMI 
(kg/m2) 
1 74 160 F 60 23.4 
2 51 158 F 50 20.0 
3 66 180 M 84 25.9 
4 49 189 M 80 22.4 
5 53 165 F 80 29.4 
6 53 175 M 170 55.5 
7 35 180 M 118 36.4 
8 65 175 M 90 29.4 
9 49 187 M 182 52.0 
10 79 160 M 70 27.3 
11 51 180 F 90 27. 8 
Median 53 175   84 27.8 
Quartile 1 50 163   75 24.7 
Quartile 3 65.5 180  104 32.9 
BMI – body mass index 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Table 2: Population pharmacokinetic parameter estimates for vancomycin in the final 
two compartment covariate model 
 Mean CV% Median 
CLPIRRT (L/h) 3.47 57.47 3.85 
CLnon-PIRRT (L/h) 2.15 96.49 1.16 
Vc (L)  41.85 58.12 26.45 
kPC (h-1) 5.29 125.65 0.32 
kCP (h-1) 5.97 132.97 0.58 
CLPIRRT, population clearance of vancomycin during PIRRT; Lnon-PIRRT, population 
clearance of vancomycin off PIRRT; Vc, population volume of distribution in the central 
compartment; kCP, rate constant for vancomycin distribution from the central to the 
peripheral compartment; kPC, rate constant for vancomycin distribution from the 
peripheral to the central compartment. 
 
Table 3. The probability of target attainment of vancomycin using various dosing 
schedules over a 24-hour period including a 12-hour PIRRT treatment or without PIRRT 
for an 80 kg patient (AUC0-24/MIC > 400 defines efficacy and AUC0-24 >700 defines 
toxicity) 
Dosing regimens 
MIC 
(mg/L) 
PIRRT Non-PIRRT 
Probability of target attainment  
AUC0-24/MIC  
>400 
AUC0-24  
>700 
AUC0-24/MIC  
>400 
AUC0-24  
>700 
10mg/kg/24h 0.5 0.960 0.040 0.959 0.025 
 1 0.391 0.040 0.435 0.025 
 2 0.019 0.040 0.012 0.025 
 4 0 0.040 0 0.025 
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15mg/kg/24h 0.5 0.995 0.113 0.994 0.099 
 1 0.543 0.113 0.578 0.099 
 2 0.053 0.113 0.043 0.099 
 4 0 0.113 0 0.099 
20mg/kg/24h 0.5 0.996 0.244 0.999 0.258 
 1 0.632 0.244 0.659 0.258 
 2 0.127 0.244 0.12 0.258 
 4 0 0.244 0 0.258 
25mg/kg/24h 0.5 0.998 0.376 1 0.412 
 1 0.721 0.376 0.746 0.412 
 2 0.247 0.376 0.26 0.412 
 4 0.005 0.376 0.001 0.412 
30mg/kg/24h 0.5 1 0.493 1 0.537 
 1 0.819 0.493 0.851 0.537 
 2 0.359 0.493 0.405 0.537 
 4 0.016 0.493 0.008 0.537 
35mg/kg/24h 0.5 1 0.565 1 0.604 
 1 0.956 0.565 0.958 0.604 
 2 0.481 0.565 0.518 0.604 
 4 0.027 0.565 0.018 0.604 
10mg/kg/12h 0.5 0.990 0.14 0.994 0.117 
 1 0.580 0.14 0.583 0.117 
 2 0.075 0.14 0.058 0.117 
 4 0 0.14 0 0.117 
15mg/kg/12h 0.5 0.997 0.355 1 0.345 
 1 0.705 0.355 0.717 0.345 
 2 0.214 0.355 0.202 0.345 
 4 0 0.355 0.001 0.345 
20mg/kg/12h 0.5 0.999 0.546 1 0.547 
 1 0.858 0.546 0.852 0.547 
 2 0.42 0.546 0.411 0.547 
 4 0.017 0.546 0.014 0.547 
25mg/kg/12h 0.5 1 0.612 1 0.626 
 1 0.988 0.612 0.986 0.626 
 2 0.564 0.612 0.57 0.626 
 4 0.047 0.612 0.033 0.626 
30mg/kg/12h 0.5 1 0.634 1 0.655 
 1 0.997 0.634 0.999 0.655 
 2 0.617 0.634 0.63 0.655 
 4 0.094 0.634 0.081 0.655 
35mg/kg/12h 0.5 1 0.676 1 0.688 
 1 0.997 0.676 1 0.688 
 2 0.633 0.676 0.652 0.688 
 4 0.154 0.676 0.152 0.688 
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PIRRT – prolonged intermittent renal replacement therapy; AUC0-24 – area under the 
concentration-time curve from 0-24 hours; MIC – minimum inhibitory concentration; 
 
